---
document_datetime: 2025-12-29 13:55:03
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/mirvaso.html
document_name: mirvaso.html
version: success
processing_time: 0.1135249
conversion_datetime: 2025-12-30 09:09:32.216276
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Mirvaso

[RSS](/en/individual-human-medicine.xml/65903)

##### Authorised

This medicine is authorised for use in the European Union

brimonidine Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Mirvaso](#news-on)
- [More information on Mirvaso](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Mirvaso. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Mirvaso.

For practical information about using Mirvaso, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Mirvaso and what is it used for?

Mirvaso is a medicine that contains the active substance brimonidine tartrate. It is used to treat the facial erythema (redness of the skin of the face) in adults with rosacea, a long-term skin condition that often causes flushing and redness.

## How is Mirvaso used?

Mirvaso is available as a gel (3 mg/g) and can only be obtained with a prescription. Mirvaso should only be applied to the skin of the face. Small amounts of gel (about pea size) are applied to the skin of the forehead, chin, nose and cheeks once a day as a thin layer. The areas should be left to dry out before applying other creams or cosmetics. For further information, see the package leaflet.

## How does Mirvaso work?

Rosacea is a skin condition affecting mainly the face. Symptoms include episodes of redness that have been linked to the widening of small blood vessels in the skin of the face, which increases the blood flow to the area.

The active substance in Mirvaso, brimonidine tartrate, works by attaching to receptors called alpha 2 -adrenergic receptors on the cells of blood vessels of the skin and activating them. This causes these blood vessels to narrow, which reduces the blood flow to the face, thus decreasing the redness.

## What benefits of Mirvaso have been shown in studies?

Mirvaso has been evaluated in two main studies involving a total of 553 patients with moderate or severe facial redness caused by rosacea. Both studies compared Mirvaso with placebo (a dummy gel) over four weeks of treatment. The main measure of effectiveness was the percentage of patients who achieved a marked reduction of facial redness at different time points (3, 6, 9 and 12 hours) on days 1, 15 and 29 after the start of the treatment.

Both studies showed that Mirvaso applied once a day was more effective than placebo at reducing the facial redness in these patients.

- In the first study, on day 1 the percentage or patients who had reduction of facial redness 3 hours after application was 16.3% (21 out of 129) for Mirvaso compared with 3.1% (4 out of 131) for placebo. Effects were maintained for 12 hours after application although the effects started to wear off after 6 hours. On day 29, 31.5% (40 out of 127) patients had reduction of facial redness 3 hours after application with Mirvaso compared with a response of 10.9% (14 out of 128) for placebo.
- In the second study, on day 1 the percentage or patients who had reduction of facial redness 3 hours after application was 19.6% (29 out of 148 patients) for Mirvaso compared with 0 % (none out of 145 patients) for placebo. Effects were also maintained for 12 hours after application and started to wear off after 6 hours. On day 29, 25.4% (36 out of 142) of patients had reduction of facial redness 3 hours after application with Mirvaso compared with a response of 9.2 % (13 out of 142) for placebo.

## What are the risks associated with Mirvaso?

The most common side effects with Mirvaso (which may affect more than 1 in 100 people), which are usually mild to moderate in severity, are erythema (redness), pruritus (itching), flushing and a burning sensation of the skin. For the full list of side effects reported with Mirvaso, see the package leaflet.

Mirvaso must not be used in children below 2 years of age or in patients receiving other medicines such as monoamine oxidase (MAO) inhibitors or certain antidepressants. Mirvaso should not be used in children or adolescents aged from 2 to 18 years. For the full list of restrictions, see the package leaflet.

## Why is Mirvaso approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Mirvaso's benefits are greater than its risks and recommended that it be approved for use in the EU. The CHMP concluded that Mirvaso improves the facial redness in patients with rosacea. Regarding safety, the CHMP acknowledged that the safety profile is acceptable since most of the adverse events reported occur locally (on the skin) and are similar to those commonly observed with other rosacea medicines applied to the skin.

## What measures are being taken to ensure the safe and effective use of Mirvaso?

A risk management plan has been developed to ensure that Mirvaso is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Mirvaso, including the appropriate precautions to be followed by healthcare professionals and patients.

Further information can be found in the [Mirvaso : EPAR - Risk-management-plan summary](/en/documents/rmp-summary/mirvaso-epar-risk-management-plan-summary_en.pdf) .

## Other information about Mirvaso

The European Commission granted a marketing authorisation valid throughout the European Union for Mirvaso on 21 February 2014.

For more information about treatment with Mirvaso, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Mirvaso : EPAR - Summary for the public

Reference Number: EMA/401/2014

English (EN) (82.2 KB - PDF)

**First published:** 14/03/2014

**Last updated:** 14/03/2014

[View](/en/documents/overview/mirvaso-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-602)

български (BG) (108.5 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/bg/documents/overview/mirvaso-epar-summary-public_bg.pdf)

español (ES) (81.45 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/es/documents/overview/mirvaso-epar-summary-public_es.pdf)

čeština (CS) (106.29 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/cs/documents/overview/mirvaso-epar-summary-public_cs.pdf)

dansk (DA) (81.06 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/da/documents/overview/mirvaso-epar-summary-public_da.pdf)

Deutsch (DE) (81.86 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/de/documents/overview/mirvaso-epar-summary-public_de.pdf)

eesti keel (ET) (80 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/et/documents/overview/mirvaso-epar-summary-public_et.pdf)

ελληνικά (EL) (106.27 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/el/documents/overview/mirvaso-epar-summary-public_el.pdf)

français (FR) (81.27 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/fr/documents/overview/mirvaso-epar-summary-public_fr.pdf)

hrvatski (HR) (100.29 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/hr/documents/overview/mirvaso-epar-summary-public_hr.pdf)

italiano (IT) (80.2 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/it/documents/overview/mirvaso-epar-summary-public_it.pdf)

latviešu valoda (LV) (104.5 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/lv/documents/overview/mirvaso-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (104.18 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/lt/documents/overview/mirvaso-epar-summary-public_lt.pdf)

magyar (HU) (100.7 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/hu/documents/overview/mirvaso-epar-summary-public_hu.pdf)

Malti (MT) (108.32 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/mt/documents/overview/mirvaso-epar-summary-public_mt.pdf)

Nederlands (NL) (84.1 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/nl/documents/overview/mirvaso-epar-summary-public_nl.pdf)

polski (PL) (108.34 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/pl/documents/overview/mirvaso-epar-summary-public_pl.pdf)

português (PT) (81.55 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/pt/documents/overview/mirvaso-epar-summary-public_pt.pdf)

română (RO) (104.65 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/ro/documents/overview/mirvaso-epar-summary-public_ro.pdf)

slovenčina (SK) (105.65 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/sk/documents/overview/mirvaso-epar-summary-public_sk.pdf)

slovenščina (SL) (101.17 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/sl/documents/overview/mirvaso-epar-summary-public_sl.pdf)

Suomi (FI) (80.11 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/fi/documents/overview/mirvaso-epar-summary-public_fi.pdf)

svenska (SV) (80.65 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

14/03/2014

[View](/sv/documents/overview/mirvaso-epar-summary-public_sv.pdf)

Mirvaso : EPAR - Risk-management-plan summary

English (EN) (83.75 KB - PDF)

**First published:** 13/05/2014

**Last updated:** 13/05/2014

[View](/en/documents/rmp-summary/mirvaso-epar-risk-management-plan-summary_en.pdf)

## Product information

Mirvaso : EPAR - Product Information

English (EN) (3.01 MB - PDF)

**First published:** 14/03/2014

**Last updated:** 04/03/2025

[View](/en/documents/product-information/mirvaso-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-261)

български (BG) (346.16 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/bg/documents/product-information/mirvaso-epar-product-information_bg.pdf)

español (ES) (2.54 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/es/documents/product-information/mirvaso-epar-product-information_es.pdf)

čeština (CS) (313.12 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/cs/documents/product-information/mirvaso-epar-product-information_cs.pdf)

dansk (DA) (355.3 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/da/documents/product-information/mirvaso-epar-product-information_da.pdf)

Deutsch (DE) (271.81 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/de/documents/product-information/mirvaso-epar-product-information_de.pdf)

eesti keel (ET) (3.24 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/et/documents/product-information/mirvaso-epar-product-information_et.pdf)

ελληνικά (EL) (386.38 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/el/documents/product-information/mirvaso-epar-product-information_el.pdf)

français (FR) (328.98 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/fr/documents/product-information/mirvaso-epar-product-information_fr.pdf)

hrvatski (HR) (2.59 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/hr/documents/product-information/mirvaso-epar-product-information_hr.pdf)

íslenska (IS) (12.39 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/is/documents/product-information/mirvaso-epar-product-information_is.pdf)

italiano (IT) (3.04 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/it/documents/product-information/mirvaso-epar-product-information_it.pdf)

latviešu valoda (LV) (2.74 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/lv/documents/product-information/mirvaso-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.57 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/lt/documents/product-information/mirvaso-epar-product-information_lt.pdf)

magyar (HU) (380.84 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/hu/documents/product-information/mirvaso-epar-product-information_hu.pdf)

Malti (MT) (3.13 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/mt/documents/product-information/mirvaso-epar-product-information_mt.pdf)

Nederlands (NL) (2.55 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/nl/documents/product-information/mirvaso-epar-product-information_nl.pdf)

norsk (NO) (2.54 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/no/documents/product-information/mirvaso-epar-product-information_no.pdf)

polski (PL) (2.65 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/pl/documents/product-information/mirvaso-epar-product-information_pl.pdf)

português (PT) (2.59 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/pt/documents/product-information/mirvaso-epar-product-information_pt.pdf)

română (RO) (3.31 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/ro/documents/product-information/mirvaso-epar-product-information_ro.pdf)

slovenčina (SK) (3.12 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/sk/documents/product-information/mirvaso-epar-product-information_sk.pdf)

slovenščina (SL) (2.59 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/sl/documents/product-information/mirvaso-epar-product-information_sl.pdf)

Suomi (FI) (3.25 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/fi/documents/product-information/mirvaso-epar-product-information_fi.pdf)

svenska (SV) (3.26 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/sv/documents/product-information/mirvaso-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0039 11/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Mirvaso : EPAR - All Authorised presentations

English (EN) (301.95 KB - PDF)

**First published:** 14/03/2014

**Last updated:** 04/03/2025

[View](/en/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-142)

български (BG) (346.81 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/bg/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_bg.pdf)

español (ES) (313.77 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/es/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_es.pdf)

čeština (CS) (345.98 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/cs/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (313.6 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/da/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (313.88 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/de/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (301.72 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/et/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (348.43 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/el/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_el.pdf)

français (FR) (1.02 MB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/fr/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (328.11 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/hr/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (311.17 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/is/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_is.pdf)

italiano (IT) (805.01 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/it/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (822.53 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/lv/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (839.38 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/lt/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (345.87 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/hu/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (822.75 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/mt/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (804.8 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/nl/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (298.42 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/no/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_no.pdf)

polski (PL) (822.64 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/pl/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_pl.pdf)

português (PT) (803.96 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/pt/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_pt.pdf)

română (RO) (823.32 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/ro/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (817.6 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/sk/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (817.94 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/sl/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (310.9 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/fi/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (298.64 KB - PDF)

**First published:**

14/03/2014

**Last updated:**

04/03/2025

[View](/sv/documents/all-authorised-presentations/mirvaso-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Mirvaso Active substance brimonidine tartrate International non-proprietary name (INN) or common name brimonidine Therapeutic area (MeSH) Skin Diseases Anatomical therapeutic chemical (ATC) code D11AX21

### Pharmacotherapeutic group

Other dermatological preparations

### Therapeutic indication

Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.

## Authorisation details

EMA product number EMEA/H/C/002642 Marketing authorisation holder

Galderma International

Tour Europlaza

Marketing authorisation issued 20/02/2014 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Mirvaso : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (154.86 KB - PDF)

**First published:** 22/10/2014

**Last updated:** 04/03/2025

[View](/en/documents/procedural-steps-after/mirvaso-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Mirvaso-H-C-PSUSA-00010093-201608: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/387250/2017

English (EN) (69.44 KB - PDF)

**First published:** 19/06/2017

**Last updated:** 19/06/2017

[View](/en/documents/scientific-conclusion/mirvaso-h-c-psusa-00010093-201608-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Mirvaso-H-C-PSUSA-00010093-201602 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/621470/2016

English (EN) (67.78 KB - PDF)

**First published:** 18/11/2016

**Last updated:** 18/11/2016

[View](/en/documents/scientific-conclusion/mirvaso-h-c-psusa-00010093-201602-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Mirvaso : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/820958/2015

English (EN) (68.78 KB - PDF)

**First published:** 08/01/2016

**Last updated:** 08/01/2016

[View](/en/documents/scientific-conclusion/mirvaso-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Mirvaso-H-C-PSUSA-00010093-201408 : EPAR - Scientific conclusions and grounds for recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/252628/2015

English (EN) (66.53 KB - PDF)

**First published:** 08/07/2015

**Last updated:** 08/07/2015

[View](/en/documents/scientific-conclusion/mirvaso-h-c-psusa-00010093-201408-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Mirvaso : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/115246/2014

English (EN) (2.06 MB - PDF)

**First published:** 14/03/2014

**Last updated:** 14/03/2014

[View](/en/documents/assessment-report/mirvaso-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Mirvaso

Adopted

Reference Number: EMA/CHMP/684313/2013

English (EN) (70.09 KB - PDF)

**First published:** 20/12/2013

**Last updated:** 20/12/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-mirvaso_en.pdf)

#### News on Mirvaso

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 December 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-december-2013) 20/12/2013

#### More information on Mirvaso

- [Safety and efficacy evaluation of Mirvaso gel 0.33 % (brimonidine tartrate) by Post marketing surveillance - post-authorisation study](https://catalogues.ema.europa.eu/study/18044)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 04/03/2025

## Share this page

[Back to top](#main-content)